A Multicenter Open-label Clinical Study on the Prevention of Premature Ovarian Failure After HSCT

Summary

HSCT is an effective method to cure hematologic malignancies. However, the reproductive system is prone to be damaged during radiotherapy and chemotherapy before transplantation, leading to ovarian failure, followed by infertility and premature ovarian failure (POF), which seriously affect the long-term quality of life of patients. This clinical trial aimed to observe the effect of Gonadotropin-releasing hormone analogues (GnRHa) on ovarian function in women of reproductive age after HSCT, so as to provide clinical evidence for whether GnRHa should be used for the prevention of POF.

Timeline

Start

2023-03-01

Primary completion

2025-10-31

Completion

2025-10-31

Drugs

Indications